---
title: "CICC Raises GENSCRIPT BIO  TP to HKD32, Results Beat Forecasts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296194907.md"
description: "CICC raised its target price for GENSCRIPT BIOto HKD32, a 78.8% increase, maintaining an 'Outperform' rating. The broker cited strong life sciences growth driven by AI4S and accelerated CDMO orders. First-half 2026 revenue rose 27.3% YoY to USD404 million, with adjusted net profit surging 203.3% to USD63 million, beating forecasts. Consequently, CIPC increased 2026 and 2027 net profit estimates by 47.7% and 51.6%, respectively."
datetime: "2026-08-18T08:11:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296194907.md)
  - [en](https://longbridge.com/en/news/296194907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296194907.md)
generator: "portal-rs"
---

# CICC Raises GENSCRIPT BIO  TP to HKD32, Results Beat Forecasts

CICC issued a report stating that GENSCRIPT BIO (01548.HK) +2.080 (+7.975%) Short selling $89.05M; Ratio 9.347% 's life sciences business recorded strong growth driven by AI4S, while CDMO orders accelerated. The broker maintained an "Outperform" rating on the company.

The report noted that, on a comparable basis, GENSCRIPT BIO's revenue for 1H26 rose 27.3% YoY to USD404 million. Net loss narrowed YoY to USD129 million, while adjusted net profit surged 203.3% YoY to USD63 million. The company's results exceeded the broker's expectations.

The broker raised its net profit forecasts for GENSCRIPT BIO for 2026 and 2027 by 47.7% and 51.6%, respectively, to USD70 million and USD109 million. Considering the long-term growth potential and improved profitability of the life sciences business benefiting from AIDD, together with the recent valuation recovery in the H-share pharmaceutical sector, the broker lifted its TP by 78.8% to HKD32.

(ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-18 12:25.)

### Related Stocks

- [01548.HK](https://longbridge.com/en/quote/01548.HK.md)
- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)
- [601995.CN](https://longbridge.com/en/quote/601995.CN.md)

## Related News & Research

- [GENSCRIPT BIO  Places Shares at 4.7% Discount, Raises Net Proceeds Exceeding HKD2.3 Billion](https://longbridge.com/en/news/298660722.md)
- [GenScript Biotech places 77,126,000 shares at HK$ 30.5 each in HK$ 2.35 billion deal](https://longbridge.com/en/news/298654891.md)
- [Genscript Biotech to Raise HK$2.33 Billion via Discounted Share Placing for AIDD Expansion](https://longbridge.com/en/news/298658184.md)
- [G Sachs: China CRO/CDMO Industry Recovery Pace Clear; Positive on WUXI Series, PHARMARON, ASYMCHEM, TIGERMED and GENSCRIPT BIO](https://longbridge.com/en/news/298712241.md)
- [Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation](https://longbridge.com/en/news/298444718.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**